Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYNJ2 | O15056 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | ALPL | P05186 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALPG | P10696 | 1/20 | 0.55 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | GALK1 | P51570 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.55 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.55 |
| ▸ | CETP | P11597 | 1/20 | 0.50 |
| ▸ | SELL | P14151 | 3/20 | 0.47 |
| ▸ | SELP | P16109 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18803979 | 0.93 | SYNJ2 (0.61) | SYNJ2KDM4EABL1ALPLPOLB | |
| SCHEMBL5704221 | 0.88 | CETP (0.57) | CETPSELLSELPSELETLR4 | |
| SCHEMBL15821144 | 0.83 | AKT1 (0.48) | SYNJ2KDM4EABL1ALPLPOLB | |
| SCHEMBL7994870 | 0.83 | AKT1 (0.48) | SYNJ2KDM4EABL1ALPLPOLB | |
| SCHEMBL9810824 | 0.83 | AKT1 (0.48) | SYNJ2KDM4EABL1ALPLPOLB | |
| SCHEMBL10612907 | 0.83 | AKT1 (0.48) | SYNJ2KDM4EABL1ALPLPOLB | |
| SCHEMBL8409353 | 0.83 | AKT1 (0.48) | SYNJ2KDM4EABL1ALPLPOLB | |
| SCHEMBL6465598 | 0.83 | AKT1 (0.48) | SYNJ2KDM4EABL1ALPLPOLB | |
| SCHEMBL6465596 | 0.83 | AKT1 (0.48) | SYNJ2KDM4EABL1ALPLPOLB | |
| SCHEMBL17010736 | 0.83 | AKT1 (0.48) | SYNJ2KDM4EABL1ALPLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9157108-B2 | Cells, nucleic acids, enzymes and use thereof, and methods for the production of sophorolipids | EVONIK DEGUSSA GMBH (DE) | 2015-10-13 | — | — | US | claimed |
| US-9068211-B2 | Cells, nucleic acids, enzymes and use thereof, and methods for the production of sophorolipids | EVONIK DEGUSSA GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20150056661-A1 | CELLS, NUCLEIC ACIDS, ENZYMES AND USE THEREOF, AND METHODS FOR THE PRODUCTION OF SOPHOROLIPIDS | EVONIK DEGUSSA GMBH (DE) | 2015-02-26 | — | — | US | disclosed |
| US-20150056659-A1 | CELLS, NUCLEIC ACIDS, ENZYMES AND USE THEREOF, AND METHODS FOR THE PRODUCTION OF SOPHOROLIPIDS | EVONIK DEGUSSA GMBH (DE) | 2015-02-26 | — | — | US | disclosed |
| US-20130035403-A1 | CELLS, NUCLEIC ACIDS, ENZYMES AND USE THEREOF, AND METHODS FOR THE PRODUCTION OF SOPHOROLIPIDS | EVONIK DEGUSSA GMBH (DE) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035403-A1 | CELLS, NUCLEIC ACIDS, ENZYMES AND USE THEREOF, AND METHODS FOR THE PRODUCTION OF SOPHOROLIPIDS | RNGTT, LIPA, POLRMT | SYNJ2 894/4885KDM4E 2664/4885ABL1 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.